TY - JOUR T1 - The impact of anti-eosinophilic therapy on exercise capacity and inspiratory muscle strength in patients with severe asthma JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00341-2022 SP - 00341-2022 AU - Elisa Franceschi AU - Nora Drick AU - Jan Fuge AU - Pierachille Santus AU - Bettina Fischer AU - Moritz Kayser AU - Tobias Welte AU - Hendrik Suhling Y1 - 2023/01/01 UR - http://openres.ersjournals.com/content/early/2022/11/10/23120541.00341-2022.abstract N2 - Asthma is a chronic respiratory disease characterized by reversible airflow limitation and heterogeneous symptoms, as wheezing, cough and dyspnea [1]. Some patients can experience exercise limitation due to exertional dyspnea and fatigue, and this is usually associated with worse quality of life (QoL) [2, 3]. Exercise limitations can be caused by different underlying mechanisms of the pulmonary, cardiovascular and muscular systems. The pathophysiological mechanisms of exertional dyspnea have been described in detail in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILDs), but limited data are available about exercise limitation in asthma [4, 5]. New antibody drugs against interleukin 5 (Il-5) and its receptor (IL5-R) approved in severe asthma demonstrated reduction of exacerbation, corticosteroid sparing and improvement of FEV1 and quality of life [6, 7].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. ER -